LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

ESPERION THERAPEUTICS INC

Aperta

SettoreSettore sanitario

2.39 -10.49

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.38

Massimo

2.72

Metriche Chiave

By Trading Economics

Entrata

28M

-13M

Vendite

17M

82M

EPS

-0.206

Margine di Profitto

-15.446

Dipendenti

304

EBITDA

37M

16M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+127.61% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

152M

448M

Apertura precedente

12.88

Chiusura precedente

2.39

Notizie sul Sentiment di mercato

By Acuity

75%

25%

346 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

ESPERION THERAPEUTICS INC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2025, 23:59 UTC

Acquisizioni, Fusioni, Takeovers

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 set 2025, 22:02 UTC

I principali Market Mover

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 set 2025, 17:01 UTC

I principali Market Mover

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 set 2025, 17:01 UTC

I principali Market Mover

Tron Shares Rise After New Investment From Bravemorning

8 set 2025, 16:14 UTC

I principali Market Mover

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 set 2025, 16:13 UTC

I principali Market Mover

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 set 2025, 23:12 UTC

Discorsi di Mercato

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 set 2025, 22:56 UTC

Discorsi di Mercato

Worst May Be Over for New Zealand Retailers -- Market Talk

8 set 2025, 22:23 UTC

Discorsi di Mercato

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 set 2025, 21:51 UTC

Discorsi di Mercato

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 set 2025, 21:47 UTC

I principali Market Mover

Microsoft Signs $17.4B AI Deal With Nebius

8 set 2025, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 set 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 set 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 set 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 set 2025, 20:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 19:33 UTC

Discorsi di Mercato

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 set 2025, 19:22 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 set 2025, 19:02 UTC

Discorsi di Mercato

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 set 2025, 18:24 UTC

Discorsi di Mercato

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 set 2025, 17:29 UTC

Discorsi di Mercato

Mexican Inflation Seen Little Changed in August -- Market Talk

8 set 2025, 16:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 set 2025, 16:36 UTC

Discorsi di Mercato

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 set 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

8 set 2025, 16:16 UTC

Utili

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 set 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 set 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

ESPERION THERAPEUTICS INC Previsione

Obiettivo di Prezzo

By TipRanks

127.61% in crescita

Previsioni per 12 mesi

Media 6.1 USD  127.61%

Alto 16 USD

Basso 1.5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ESPERION THERAPEUTICS INC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

3

Acquista

1

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

0.85 / 1.05Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

346 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
help-icon Live chat